PAS
TNYA icon

Point72 Asia (Singapore)’s Tenaya Therapeutics TNYA Stock Holding History

Point72 Asia (Singapore)’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$28.4K Sell
17,560
-17,464
-50% -$17.6K ﹤0.01% 648
2025
Q2 		$21.4K Buy
+35,024
New +$17.8K ﹤0.01% 724

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Point72 Asia (Singapore)'s TNYA Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Tenaya Therapeutics (TNYA) stake by 50% in Q3 2025, selling an estimated $17.6K and leaving 17,560 shares worth $28.4K. The position accounts for ﹤0.01% of the portfolio, ranked #648.

Point72 Asia (Singapore) first reported a position in TNYA in Q2 2025 and has held it in 2 quarters since. 91 funds tracked by Wall St. Rank hold TNYA as of Q3 2025.

  • Point72 Asia (Singapore) held 17,560 shares of Tenaya Therapeutics worth $28.4K as of Q3 2025.
  • Point72 Asia (Singapore) sold 17,464 Tenaya Therapeutics shares in Q3 2025, an estimated $17.6K.
  • Tenaya Therapeutics made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #648 holding.
  • Point72 Asia (Singapore) first reported a position in Tenaya Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 91 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.